Central nervous system HIV infection in less-drug regimen antiretroviral therapy simplification strategies

Seminars in Neurology

Volumn 34, Issue 1, 2014, Pages 78-88

  Ferretti, Francesca ^a   Gianotti, Nicola ^a   Lazzarin, Adriano ^a   Cinque, Paola ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

central nervous system; cerebrospinal fluid; cerebrospinal fluid viral escape; dual therapy; monotherapy

Indexed keywords

AMPRENAVIR; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; HETERODUPLEX; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; TENOFOVIR; ANTIRETROVIRUS AGENT; NEUROPROTECTIVE AGENT;

ARTICLE; ATTENTION; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; COGNITION; DRUG EFFICACY; EXECUTIVE FUNCTION; GENETIC DISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MEMORY; MICROGLIA; MOLECULAR CLONING; MONOTHERAPY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PLEOCYTOSIS; PRIMARY INFECTION; PRIORITY JOURNAL; RESERVOIR; TASK PERFORMANCE; TREATMENT RESPONSE; UPREGULATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; CENTRAL NERVOUS SYSTEM INFECTIONS; COMPLICATION; HIV INFECTIONS;

ANTI-RETROVIRAL AGENTS; CENTRAL NERVOUS SYSTEM INFECTIONS; HIV INFECTIONS; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 84898422322     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1372345     Document Type: Article

References (76)

1. Mathis S., Khanlari B., Pulido F., et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS ONE: 2011; 6 7 e22003
2. McKinnon J. E., Mellors J. W., Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther: 2009; 14 1 1 12
3. Delfraissy J. F., Flandre P., Delaugerre C., et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS: 2008; 22 3 385 393
4. Ghosn J., Flandre P., Cohen-Codar I., et al. MONARK Study Group. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med: 2010; 11 2 137 142
5. Pérez-Valero I., Arribas J. R. Protease inhibitor monotherapy. Curr Opin Infect Dis: 2011; 24 1 7 11
6. Arribas J. R., Delgado R., Arranz A., et al. OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr: 2009; 51 2 147 152
7. Santos J. R., Moltó J., Llibre J. M., et al. Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile. PLoS ONE: 2012; 7 5 e37442
8. Katlama C., Valantin M. A., Algarte-Genin M., et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS: 2010; 24 15 2365 2374
9. Valantin M. A., Lambert-Niclot S., Flandre P., et al. MONOI ANRS 136 Study Group. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother: 2012; 67 3 691 695
10. Arribas J. R., Horban A., Gerstoft J., et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS: 2010; 24 2 223 230
11. Clumeck N., Rieger A., Banhegyi D., et al. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. J Antimicrob Chemother: 2011; 66 8 1878 1885
12. Vernazza P., Daneel S., Schiffer V., et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS: 2007; 21 10 1309 1315 (Pubitemid 46883485)
13. Saumoy M., Tiraboschi J., Gutierrez M., et al. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV Med: 2011; 12 7 438 441
14. Burgos J., Crespo M., Falcó V., et al. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. J Antimicrob Chemother: 2012; 67 10 2479 2486
15. Calin R., Paris L., Simon A., et al. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy. Antivir Ther: 2012; 17 8 1601 1604
16. Negredo E., Moltó J., Burger D., et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr: 2005; 38 1 47 52 (Pubitemid 40094118)
17. Okoli C., Siccardi M., Thomas-William S., et al. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother: 2012; 67 3 671 674
18. Cordery D. V., Hesse K., Amin J., Cooper D. A. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther: 2010; 15 7 1035 1038
19. Di Giambenedetto S., Fabbiani M., Colafigli M., et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother: 2013; 68 6 1364 1372
20. Ofotokun I., Sheth A. N., Sanford S. E., et al. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses: 2012; 28 10 1196 1206
21. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2013. Available at: http://aidsinfo.nih.gov/guidelines. Accessed December 1, 2013
22. Thompson M. A., Aberg J. A., Hoy J. F., et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA: 2012; 308 4 387 402
23. European AIDS Clinical Society Guidelines. European AIDS Clinical Society (EACS), 2013. Available at: http://www.eacsociety.org. Accessed December 1, 2013
24. HIV-AIDS Italian Expert Panel Italian guidelines for the use of antiretroviral agents and diagnostic-clinical management of HIV-1 infected persons 2013. Italian Ministry of Health. Available at: http://www.salute.gov. it/imgs/C-17-pubblicazioni-2074-allegato.pdf. Accessed December 1, 2013
25. D'Arminio Monforte A., Gianotti N., Cozzi-Lepri A., Pinnetti C., et al. Durability of lopinavir/ritonavir mono-therapy in individuals with viral load ≤50 copies/mL in the observational setting. Antivir Ther: 2013;. [Epub ahead of print]
26. Ritola K., Robertson K., Fiscus S. A., Hall C., Swanstrom R. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol: 2005; 79 16 10830 10834 (Pubitemid 41098622)
27. Strain M. C., Letendre S., Pillai S. K., et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol: 2005; 79 3 1772 1788 (Pubitemid 40459123)
28. Gorry P. R., Taylor J., Holm G. H., et al. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol: 2002; 76 12 6277 6292 (Pubitemid 34556323)
29. Gorry P. R., Bristol G., Zack J. A., et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol: 2001; 75 21 10073 10089 (Pubitemid 32948038)
30. Spudich S., Gisslen M., Hagberg L., et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis: 2011; 204 5 753 760
31. Tambussi G., Gori A., Capiluppi B., et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis: 2000; 30 6 962 965 (Pubitemid 32250348)
32. Davis L. E., Hjelle B. L., Miller V. E., et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology: 1992; 42 9 1736 1739
33. Scaravilli F., Bazille C., Gray F. Neuropathologic contributions to understanding AIDS and the central nervous system. Brain Pathol: 2007; 17 2 197 208 (Pubitemid 46466132)
34. Spudich S., González-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med: 2012; 2 6 a007120
35. Giri M. S., Nebozyhn M., Raymond A., et al. Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J Immunol: 2009; 182 7 4459 4470
36. Clements J. E., Babas T., Mankowski J. L., et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis: 2002; 186 7 905 913
37. Zink M. C., Brice A. K., Kelly K. M., et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis: 2010; 202 1 161 170
38. Bestetti A., Presi S., Pierotti C., et al. Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J Neurovirol: 2004; 10 01 52 57 (Pubitemid 38325094)
39. Di Stefano M., Sabri F., Leitner T., et al. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol: 1995; 33 2 352 355
40. Lanier E. R., Sturge G., McClernon D., et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS: 2001; 15 6 747 751 (Pubitemid 32423222)
41. Stingele K., Haas J., Zimmermann T., et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology: 2001; 56 3 355 361 (Pubitemid 32144147)
42. Venturi G., Catucci M., Romano L., et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis: 2000; 181 2 740 745 (Pubitemid 30131851)
43. Canestri A., Lescure F. X., Jaureguiberry S., et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis: 2010; 50 5 773 778
44. Peluso M. J., Ferretti F., Peterson J., et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS: 2012; 26 14 1765 1774
45. Edén A., Fuchs D., Hagberg L., et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis: 2010; 202 12 1819 1825
46. Gutmann C., Cusini A., Günthard H. F., et al. Swiss HIV Cohort Study (SHCS). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS: 2010; 24 15 2347 2354
47. Spudich S., Lollo N., Liegler T., Deeks S. G., Price R. W. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis: 2006; 194 12 1686 1696 (Pubitemid 44901999)
48. Aquaro S., Svicher V., Schols D., et al. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leukoc Biol: 2006; 80 5 1103 1110 (Pubitemid 44646315)
49. Hagberg L., Gisslen M., Norkrans G., Svennerholm B. Kinetics of HIV-1 in cerebrospinal fluid and serum after zidovudine treatment. J Neuro-Aids: 1999; 2 2 29 35 (Pubitemid 30012139)
50. Gisolf E. H., Enting R. H., Jurriaans S., et al. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/ stavudine. AIDS: 2000; 14 11 1583 1589
51. Foudraine N. A., Hoetelmans R. M., Lange J. M., et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet: 1998; 351 9115 1547 1551 (Pubitemid 28230890)
52. Strazielle N., Ghersi-Egea J. F. Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol: 2005; 15 2 105 133 (Pubitemid 40343194)
53. Letendre S., Marquie-Beck J., Capparelli E., et al. CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol: 2008; 65 1 65 70
54. van Praag R. M., Weverling G. J., Portegies P., et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS: 2000; 14 9 1187 1194 (Pubitemid 30420662)
55. Haas D. W., Johnson B., Nicotera J., et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother: 2003; 47 7 2131 2137 (Pubitemid 36753562)
56. Isaac A., Taylor S., Cane P., et al. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother: 2004; 54 2 498 502 (Pubitemid 39177476)
57. Yilmaz A., Ståhle L., Hagberg L., Svennerholm B., Fuchs D., Gisslén M. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand J Infect Dis: 2004; 36 11-12 823 828 (Pubitemid 40074016)
58. Cusini A., Vernazza P. L., Yerly S., et al. Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr: 2013; 62 1 28 35
59. Capparelli E. V., Holland D., Okamoto C., et al. HNRC Group. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS: 2005; 19 9 949 952 (Pubitemid 40834938)
60. DiCenzo R., DiFrancesco R., Cruttenden K., Donnelly J., Schifitto G. Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults. Ann Pharmacother: 2009; 43 12 1972 1977
61. Yilmaz A., Izadkhashti A., Price R. W., et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses: 2009; 25 4 457 461
62. Croteau D., Rossi S. S., Best B. M., et al. CHARTER Group. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother: 2013; 68 3 684 689
63. Calcagno A., Yilmaz A., Cusato J., et al. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS: 2012; 26 12 1529 1533
64. Best B. M., Letendre S. L., Brigid E., et al. CHARTER Group. Low atazanavir concentrations in cerebrospinal fluid. AIDS: 2009; 23 1 83 87
65. Croteau D., Letendre S., Best B. M., et al. CHARTER Group. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother: 2012; 56 4 1985 1989
66. Gisslén M., Fuchs D., Hagberg L., Svennerholm B., Zetterberg H. Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis: 2012; 44 12 997 1000
67. de Truchis P., Mathez D., Abe E., et al. Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy. AIDS: 2010; 24 8 1235 1236
68. Pasquet A., Ajana F., Melliez H., Giurca C., Poissy J., Yazdanpanah Y. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS: 2012; 26 13 1726 1728
69. Santos J. R., Muñoz-Moreno J. A., Moltó J., et al. Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. PLoS ONE: 2013; 8 7 e70201
70. Paton N. I., Meynard J. L., Pulido F., Arenas-Pinto A., Girard P. M., Arribas J. Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial. AIDS: 2011; 25 3 393 394
71. Worthington M. G., Ross J. J. Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. AIDS: 2003; 17 14 2145 2146 (Pubitemid 37297173)
72. Knysz B., Gasiorowski J., Czarnecki M., Gladysz A. Viral rebound syndrome in two HIV-1-positive patients after structured treatment interruption. Viral Immunol: 2005; 18 3 579 581
73. Letendre S. L., Brande G., Hermes A., et al. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis: 2007; 45 11 1511 1517 (Pubitemid 351411885)
74. Casado J. L., de la Calle C., del Palacio M., Perez-Elías M. J., Moreno A., Moreno S. Short communication: lamivudine plus a boosted-protease inhibitor as simplification strategy in HIV-infected patients: proof of concept. AIDS Res Hum Retroviruses: 2013; 29 3 588 591
75. Bunupuradah T., Chetchotisakd P., Jirajariyavej S., et al. HIV STAR Study Group. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy. J Neurovirol: 2012; 18 6 479 487
76. Robertson K. R., Su Z., Margolis D. M., et al. A5170 Study Team. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology: 2010; 74 16 1260 1266